Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|July 22, 2016
EMA Recommends Approval of First HIV Pre-Exposure Prophylaxis Drug in the EU
Author(s)Pharmaceutical Technology Editors
The agency has recommended granting marketing authorization in the EU for Truvada.
Advertisement
The European Medicines Agency (EMA) announced on July 22, 2016 that it was recommending marketing authorization for Truvada (emtricitabine/tenofovir disoproxil) in the European Union. Truvada is taken as a pre-exposure prophylaxis (PrEP) measure to reduce the risk of sexually-acquired HIV type 1 (HIV-1) infection in adults at high risk.
Truvada is the first drug to be approved in the EU for PrEP and is used as a part of an overall HIV infection prevention strategy that includes safe-sex practices, including the use of condoms.
Truvada was originally authorized in the EU in 2005 to treat HIV-1 infection in adults in combination with other antiviral medications. According to EMA, “Truvada contains two active substances, emtricitabine and tenofovir disoproxil, which is a ‘prodrug’ of tenofovir. This means that it is converted into tenofovir in the body. Emtricitabine and tenofovir work in similar ways by blocking the activity of viral reverse transcriptase, which is necessary for the virus to multiply.”
Studies showed substantial reduction in the risk of HIV-1 when Truvada was used as a prophylactic. In one study, the drug reduced the risk of HIV infection in 2499 HIV-negative men and transgender women who have sex with men by 42%, compared with placebo. Truvada reduced the risk of infection by 75% in the second study, which involved 4758 heterosexual couples where one partner was HIV-positive and the other was not. The study also evaluated the efficacy and safety of Truvada or tenofovir alone versus placebo.
Source:
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement